Adverse Effects of Immunosuppression: Infections.

Graft vs Host Disease / etiology Hematopoietic Stem Cell Transplantation / adverse effects Humans Immunosuppression Therapy / adverse effects
Immunocompromised hosts Immunosuppression Opportunistic infection Transplant and immunocompromised infectious diseases

Journal

Handbook of experimental pharmacology
ISSN: 0171-2004
Titre abrégé: Handb Exp Pharmacol
Pays: Germany
ID NLM: 7902231

Informations de publication

Date de publication:
2022
Historique:
pubmed: 22 10 2021
medline: 9 7 2022
entrez: 21 10 2021
Statut: ppublish

Résumé

Immunosuppressive therapies are currently indicated for a wide range of diseases. As new agents emerge and indications evolve the landscape grows increasingly complex. Therapies can target pathologic immune system over-activation in rheumatologic or autoimmune disease, or conditioning and graft versus host disease (GVHD) prophylactic regimens may eliminate or inhibit host immune function to improve graft survival and risk of complication in solid organ transplantation (SOT) or hematopoietic stem cell transplantation (HSCT). With immunosuppressive therapy, infections occur. Complex disease states, host factors, and concomitant therapies contribute to a "net state" of immunosuppression that must be considered and may confound perceived increased infection risks in patients receiving treatment.

Identifiants

DOI: 10.1007/164_2021_550 PMID: 34671868
pubmed: 34671868
doi: 10.1007/164_2021_550
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

287-314

Informations de copyright

© 2021. Springer Nature Switzerland AG.

Références

Achtnichts L, Obreja O, Conen A, Fux CA, Nedeltchev K (2015) Cryptococcal meningoencephalitis in a patient with multiple sclerosis treated with fingolimod. JAMA Neurol 72(10):1203–1205
pubmed: 26457631 doi: 10.1001/jamaneurol.2015.1746
Adams AB, Goldstein J, Garrett C et al (2017) Belatacept combined with transient calcineurin inhibitor therapy prevents rejection and promotes improved long-term renal allograft function. Am J Transplant 17(11):2922–2936
pubmed: 28544101 pmcid: 5868947 doi: 10.1111/ajt.14353
Allison AC, Eugui EM (2005) Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 80(2 Suppl):S181–S190
pubmed: 16251851 doi: 10.1097/01.tp.0000186390.10150.66
Ansari D, Lund LH, Stehlik J et al (2015) Induction with anti-thymocyte globulin in heart transplantation is associated with better long-term survival compared with basiliximab. J Heart Lung Transplant 34(10):1283–1291
pubmed: 26087667 doi: 10.1016/j.healun.2015.04.001
Arai Y, Jo T, Matsui H, Kondo T, Takaori-Kondo A (2017) Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Leuk Lymphoma 58(8):1840–1848
pubmed: 27951736 doi: 10.1080/10428194.2016.1266624
Ariza-Heredia EJ, Nesher L, Chemaly RF (2014) Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review. Cancer Lett 342(1):1–8
pubmed: 24041869 doi: 10.1016/j.canlet.2013.09.004
Arvin AM, Wolinsky JS, Kappos L et al (2015) Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol 72(1):31–39
pubmed: 25419615 pmcid: 5391035 doi: 10.1001/jamaneurol.2014.3065
Barmettler S, Ong MS, Farmer JR, Choi H, Walter J (2018) Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open 1(7):e184169
pubmed: 30646343 pmcid: 6324375 doi: 10.1001/jamanetworkopen.2018.4169
Basic-Jukic N, Kes P, Bubic-Filipi LJ et al (2005) Does mycophenolate mofetil increase the incidence of cytomegalovirus disease compared with azathioprine after cadaveric kidney transplantation? Transplant Proc 37(2):850–851
pubmed: 15848553 doi: 10.1016/j.transproceed.2004.12.228
Berger JR (2017) Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord 12:59–63
pubmed: 28283109 doi: 10.1016/j.msard.2017.01.006
Bergstrom L, Yocum DE, Ampel NM et al (2004) Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum 50(6):1959–1966
pubmed: 15188373 doi: 10.1002/art.20454
Berzero G, Basso S, Stoppini L et al (2021) Adoptive transfer of JC virus-specific T lymphocytes for the treatment of progressive multifocal leukoencephalopathy. Ann Neurol 89(4):769–779
pubmed: 33459417 pmcid: 8248385 doi: 10.1002/ana.26020
Biehl A, Harinstein L, Brinker A, Glaser R, Munoz M, Avigan M (2021) A case series analysis of serious exacerbations of viral hepatitis and non-viral hepatic injuries in tocilizumab-treated patients. Liver Int 41(3):515–528
pubmed: 33320444 doi: 10.1111/liv.14766
Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D, Thymoglobulin Induction Study Group (2006) Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 355(19):1967–1977
pubmed: 17093248 doi: 10.1056/NEJMoa060068
Breuer GS, Ehrenfeld M, Rosner I et al (2014) Late-onset neutropenia following rituximab treatment for rheumatologic conditions. Clin Rheumatol 33(9):1337–1340
pubmed: 24599679 doi: 10.1007/s10067-014-2562-x
Brew BJ, Davies NW, Cinque P, Clifford DB, Nath A (2010) Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol 6(12):667–679
pubmed: 21131916 doi: 10.1038/nrneurol.2010.164
Burmester GR, Rubbert-Roth A, Cantagrel A et al (2014) A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 73(1):69–74
pubmed: 23904473 doi: 10.1136/annrheumdis-2013-203523
Buti M, Manzano ML, Morillas RM et al (2017) Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: the Preblin study. PLoS One 12(9):e0184550
pubmed: 28898281 pmcid: 5595327 doi: 10.1371/journal.pone.0184550
Calabresi PA, Radue EW, Goodin D et al (2014) Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 13(6):545–556
pubmed: 24685276 doi: 10.1016/S1474-4422(14)70049-3
Campbell L, Chen C, Bhagat SS, Parker RA, Ostor AJ (2011) Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford) 50(3):552–562
doi: 10.1093/rheumatology/keq343
Caocci G, Murgia F, Podda L, Solinas A, Atzeni S, La Nasa G (2014) Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia 28(1):225–227
pubmed: 23929216 doi: 10.1038/leu.2013.235
Carson KR, Newsome SD, Kim EJ et al (2014) Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer 120(16):2464–2471
pubmed: 24771533 doi: 10.1002/cncr.28712
Casulo C, Maragulia J, Zelenetz AD (2013) Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk 13(2):106–111
pubmed: 23276889 doi: 10.1016/j.clml.2012.11.011
Charpentier B, Rostaing L, Berthoux F et al (2003) A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation 75(6):844–851
pubmed: 12660513 doi: 10.1097/01.TP.0000056635.59888.EF
Chen YM, Huang WN, Wu YD et al (2018) Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study. Ann Rheum Dis 77(5):780–782
pubmed: 28663308 doi: 10.1136/annrheumdis-2017-211322
Choi J, Aubert O, Vo A et al (2017) Assessment of tocilizumab (anti-Interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. Am J Transplant 17(9):2381–2389
pubmed: 28199785 doi: 10.1111/ajt.14228
Chun J, Hartung HP (2010) Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 33(2):91–101
pubmed: 20061941 pmcid: 2859693 doi: 10.1097/WNF.0b013e3181cbf825
Cohen SB, Moreland LW, Cush JJ et al (2004) A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 63(9):1062–1068
pubmed: 15082469 pmcid: 1755108 doi: 10.1136/ard.2003.016014
Cohen JA, Barkhof F, Comi G et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362(5):402–415
pubmed: 20089954 doi: 10.1056/NEJMoa0907839
Cohen SB, Tanaka Y, Mariette X et al (2017) Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 76(7):1253–1262
pubmed: 28143815 doi: 10.1136/annrheumdis-2016-210457
Coiffier B, Lepretre S, Pedersen LM et al (2008) Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 111(3):1094–1100
pubmed: 18003886 doi: 10.1182/blood-2007-09-111781
Colomba C, Rubino R, Siracusa L et al (2012) Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. BMC Res Notes 5:552
pubmed: 23039051 pmcid: 3515333 doi: 10.1186/1756-0500-5-552
Colombel JF, Sands BE, Rutgeerts P et al (2017) The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 66(5):839–851
pubmed: 26893500 doi: 10.1136/gutjnl-2015-311079
Comi G, Kappos L, Selmaj KW et al (2019) Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol 18(11):1009–1020
pubmed: 31492651 doi: 10.1016/S1474-4422(19)30239-X
Confavreux C, O'Connor P, Comi G et al (2014) Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 13(3):247–256
pubmed: 24461574 doi: 10.1016/S1474-4422(13)70308-9
Couriel D, Saliba R, Hicks K et al (2004) Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 104(3):649–654
pubmed: 15069017 doi: 10.1182/blood-2003-12-4241
Creed TJ, Norman MR, Probert CS et al (2003) Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 18(1):65–75
pubmed: 12848627 doi: 10.1046/j.1365-2036.2003.01639.x
Cronstein BN (1996) Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 39(12):1951–1960
pubmed: 8961899 doi: 10.1002/art.1780391203
Danese S, Vermeire S, Hellstern P et al (2019) Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II). Gut 68(1):40–48
pubmed: 29247068 doi: 10.1136/gutjnl-2017-314562
De Benedetti F, Gattorno M, Anton J et al (2018) Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med 378(20):1908–1919
pubmed: 29768139 doi: 10.1056/NEJMoa1706314
den Broeder AA, Creemers MC, Fransen J et al (2007) Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 34(4):689–695
Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH (2015) Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 61(2):703–711
pubmed: 25412906 doi: 10.1002/hep.27609
Dixon WG, Hyrich KL, Watson KD et al (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69(3):522–528
pubmed: 19854715 doi: 10.1136/ard.2009.118935
Dougados M, van der Heijde D, Chen YC et al (2017) Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 76(1):88–95
pubmed: 27689735 doi: 10.1136/annrheumdis-2016-210094
Drobyski WR, Pasquini M, Kovatovic K et al (2011) Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol Blood Marrow Transplant 17(12):1862–1868
pubmed: 21745454 pmcid: 3716013 doi: 10.1016/j.bbmt.2011.07.001
Durrbach A, Pestana JM, Florman S et al (2016) Long-term outcomes in belatacept- versus cyclosporine-treated recipients of extended criteria donor kidneys: final results from BENEFIT-EXT, a phase III randomized study. Am J Transplant 16(11):3192–3201
pubmed: 27130868 pmcid: 5516151 doi: 10.1111/ajt.13830
Emery P, Keystone E, Tony HP et al (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67(11):1516–1523
pubmed: 18625622 doi: 10.1136/ard.2008.092932
Emre S, Gondolesi G, Polat K et al (2001) Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 7(3):220–225
pubmed: 11244163 doi: 10.1053/jlts.2001.22455
Epstein DJ, Dunn J, Deresinski S (2018) Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management. Open Forum Infect Dis 5(8):ofy174
pubmed: 30094293 pmcid: 6080056 doi: 10.1093/ofid/ofy174
Feagan BG, Rutgeerts P, Sands BE et al (2013) Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369(8):699–710
pubmed: 23964932 doi: 10.1056/NEJMoa1215734
Fine AJ, Sorbello A, Kortepeter C, Scarazzini L (2013) Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients. Clin Infect Dis 57(6):849–852
pubmed: 23728144 doi: 10.1093/cid/cit376
Fleischmann RM, Schechtman J, Bennett R et al (2003) Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum 48(4):927–934
pubmed: 12687534 doi: 10.1002/art.10870
Fleischmann RM, Tesser J, Schiff MH et al (2006) Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 65(8):1006–1012
pubmed: 16396977 pmcid: 1798263 doi: 10.1136/ard.2005.048371
Fleischmann R, Kremer J, Cush J et al (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367(6):495–507
pubmed: 22873530 doi: 10.1056/NEJMoa1109071
Focosi D, Tuccori M, Maggi F (2019) Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: what do we know after 20 years of rituximab. Rev Med Virol 29(6):e2077
pubmed: 31369199 doi: 10.1002/rmv.2077
Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P (2011) Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 106(4):644–659, quiz 660
pubmed: 21407183 doi: 10.1038/ajg.2011.73
Fox RJ, Miller DH, Phillips JT et al (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367(12):1087–1097
pubmed: 22992072 doi: 10.1056/NEJMoa1206328
Galloway JB, Hyrich KL, Mercer LK et al (2011) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 50(1):124–131
doi: 10.1093/rheumatology/keq242
Gerards AH, de Lathouder S, de Groot ER, Dijkmans BA, Aarden LA (2003) Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford) 42(10):1189–1196
doi: 10.1093/rheumatology/keg323
Gold R, Kappos L, Arnold DL et al (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367(12):1098–1107
pubmed: 22992073 doi: 10.1056/NEJMoa1114287
Gopal AK, Ramchandren R, O'Connor OA et al (2012) Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 120(3):560–568
pubmed: 22510871 pmcid: 3731651 doi: 10.1182/blood-2011-12-397893
Grim SA, Pham T, Thielke J et al (2007) Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients. Clin Transpl 21(5):628–632
doi: 10.1111/j.1399-0012.2007.00700.x
Grinyo J, Charpentier B, Pestana JM et al (2010) An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 90(12):1521–1527
pubmed: 21088650 doi: 10.1097/TP.0b013e3182007b95
Gross CM, Baumgartner A, Rauer S, Stich O (2012) Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod. Neurology 79(19):2006–2007
pubmed: 23035074 doi: 10.1212/WNL.0b013e3182735d24
Grover R, Dhir V, Aneja R et al (2006) Severe infections following leflunomide therapy for rheumatoid arthritis. Rheumatology (Oxford) 45(7):918–920
doi: 10.1093/rheumatology/kel130
Gupta G, Lautenbach E, Lewis JD (2006) Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 4(12):1483–1490
pubmed: 17162240 doi: 10.1016/j.cgh.2006.09.019
Hambach L, Stadler M, Dammann E, Ganser A, Hertenstein B (2002) Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation. Bone Marrow Transplant 29(11):903–906
pubmed: 12080355 doi: 10.1038/sj.bmt.1703583
Harrington JE, Hamilton RE, Ganley-Leal L, Farraye FA, Wasan SK (2020) The immunogenicity of the influenza, pneumococcal, and hepatitis B vaccines in patients with inflammatory bowel disease treated with vedolizumab. Crohn’s Colitis 360 2(4):otaa082
doi: 10.1093/crocol/otaa082
Harris J, Hope JC, Keane J (2008) Tumor necrosis factor blockers influence macrophage responses to mycobacterium tuberculosis. J Infect Dis 198(12):1842–1850
pubmed: 18954258 doi: 10.1086/593174
Harvey J, Tran L, Sampath R, White C, Campanile T (2019) 1410. Serious cryptococcal infections with ruxolitinib use: a case of meningitis and a review of the literature. Open Forum Infect Dis 6(Suppl 2):S513–S514
pmcid: 6809270 doi: 10.1093/ofid/ofz360.1274
Hauser SL, Kappos L, Arnold DL et al (2020) Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology 95(13):e1854–e1867
pubmed: 32690791 pmcid: 7682822 doi: 10.1212/WNL.0000000000010376
Hershberger RE, Starling RC, Eisen HJ et al (2005) Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 352(26):2705–2713
pubmed: 15987919 doi: 10.1056/NEJMoa032953
Hillen ME, Cook SD, Samanta A, Grant E, Quinless JR, Rajasingham JK (2015) Fatal acute liver failure with hepatitis B virus infection during nataluzimab treatment in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2(2):e72
pubmed: 25815364 pmcid: 4335813 doi: 10.1212/NXI.0000000000000072
Hillmen P, Skotnicki AB, Robak T et al (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25(35):5616–5623
pubmed: 17984186 doi: 10.1200/JCO.2007.12.9098
Hirsch HH, Yakhontova K, Lu M, Manzetti J (2016) BK polyomavirus replication in renal tubular epithelial cells is inhibited by sirolimus, but activated by tacrolimus through a pathway involving FKBP-12. Am J Transplant 16(3):821–832
pubmed: 26639422 doi: 10.1111/ajt.13541
Hoffman HM, Throne ML, Amar NJ et al (2008) Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 58(8):2443–2452
pubmed: 18668535 doi: 10.1002/art.23687
Hookey LC, Depew W, Boag A, Vanner S (2003) 6-mercaptopurine and inflammatory bowel disease: hidden ground for the cytomegalovirus. Can J Gastroenterol 17(5):319–322
pubmed: 12772006 doi: 10.1155/2003/824547
Hoppe-Seyler K, Sauer P, Lohrey C, Hoppe-Seyler F (2012) The inhibitors of nucleotide biosynthesis leflunomide, FK778, and mycophenolic acid activate hepatitis B virus replication in vitro. Hepatology 56(1):9–16
pubmed: 22271223 doi: 10.1002/hep.25602
Huang H, Li X, Zhu J et al (2014) Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA 312(23):2521–2530
pubmed: 25514302 doi: 10.1001/jama.2014.15704
Iannone F, Ferraccioli G, Sinigaglia L et al (2018) Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics’ register GISEA. Clin Rheumatol 37(2):315–321
pubmed: 28980085 doi: 10.1007/s10067-017-3846-8
Ibrahim A, Ahmed M, Conway R, Carey JJ (2018) Risk of infection with methotrexate therapy in inflammatory diseases: a systematic review and meta-analysis. J Clin Med 8(1):15
pmcid: 6352130 doi: 10.3390/jcm8010015
Issa NC, Fishman JA (2009) Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis 48(6):772–786
pubmed: 19207081 doi: 10.1086/597089
Ito H, Takazoe M, Fukuda Y et al (2004) A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology 126(4):989–996; discussion 947
pubmed: 15057738 doi: 10.1053/j.gastro.2004.01.012
Jain AB, Hamad I, Rakela J et al (1998) A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. Transplantation 66(10):1395–1398
pubmed: 9846530 pmcid: 2952474 doi: 10.1097/00007890-199811270-00024
Jick H, Myers MW, Dean AD (1995) The risk of sulfasalazine- and mesalazine-associated blood disorders. Pharmacotherapy 15(2):176–181
pubmed: 7624265
Jorge S, Guerra J, Santana A, Mil-Homens C, Prata MM (2008) Mycophenolate mofetil: ten years’ experience of a renal transplant unit. Transplant Proc 40(3):700–704
pubmed: 18454991 doi: 10.1016/j.transproceed.2008.02.028
Judge TA, Tang A, Spain LM, Deans-Gratiot J, Sayegh MH, Turka LA (1996) The in vivo mechanism of action of CTLA4Ig. J Immunol 156(6):2294–2299
pubmed: 8690920
Kalb RE, Fiorentino DF, Lebwohl MG et al (2015) Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatol 151(9):961–969
pubmed: 25970800 doi: 10.1001/jamadermatol.2015.0718
Kamar N, Milioto O, Puissant-Lubrano B et al (2010) Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 10(1):89–98
pubmed: 19656128 doi: 10.1111/j.1600-6143.2009.02785.x
Kaneko Y, Suwa A, Ikeda Y, Hirakata M (2006) Pneumocystis jiroveci pneumonia associated with low-dose methotrexate treatment for rheumatoid arthritis: report of two cases and review of the literature. Mod Rheumatol 16(1):36–38
pubmed: 16622722 doi: 10.3109/s10165-005-0443-5
Kang HM, Kim SK, Lee JW, Chung NG, Cho B (2021) Efficacy of low dose antithymocyte globulin on overall survival, relapse rate, and infectious complications following allogeneic peripheral blood stem cell transplantation for leukemia in children. Bone Marrow Transplant 56(4):890–899
pubmed: 33199818 doi: 10.1038/s41409-020-01121-9
Kantarjian HM, DeAngelo DJ, Stelljes M et al (2016) Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 375(8):740–753
pubmed: 27292104 pmcid: 5594743 doi: 10.1056/NEJMoa1509277
Kappos L, Radue EW, O'Connor P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362(5):387–401
pubmed: 20089952 doi: 10.1056/NEJMoa0909494
Kappos L, Bar-Or A, Cree BAC et al (2018) Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 391(10127):1263–1273
pubmed: 29576505 doi: 10.1016/S0140-6736(18)30475-6
Karadkhele G, Hogan J, Magua W et al (2021) CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept. Am J Transplant 21(1):208–221
pubmed: 32519434 doi: 10.1111/ajt.16132
Kavanaugh A, Ritchlin C, Rahman P et al (2014) Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis 73(6):1000–1006
pubmed: 24553909 doi: 10.1136/annrheumdis-2013-204741
Kelesidis T, Daikos G, Boumpas D, Tsiodras S (2011) Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis 15(1):e2–e16
pubmed: 21074471 doi: 10.1016/j.ijid.2010.03.025
KESIMPTA
Keystone EC, Genovese MC, Klareskog L et al (2009) Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study. Ann Rheum Dis 68(6):789–796
pubmed: 19066176 doi: 10.1136/ard.2008.099010
Keystone EC, Taylor PC, Drescher E et al (2015) Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 74(2):333–340
pubmed: 25431052 doi: 10.1136/annrheumdis-2014-206478
Knoll GA, Kokolo MB, Mallick R et al (2014) Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ 349:g6679
pubmed: 25422259 pmcid: 4241732 doi: 10.1136/bmj.g6679
Komatsuda A, Okamoto Y, Hatakeyama T, Wakui H, Sawada K (2008) Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus. Clin Rheumatol 27(3):395–397
pubmed: 17952482 doi: 10.1007/s10067-007-0753-4
Koo S, Marty FM, Baden LR (2011) Infectious complications associated with immunomodulating biologic agents. Hematol Oncol Clin North Am 25(1):117–138
pubmed: 21236394 doi: 10.1016/j.hoc.2010.11.009
Kremer J, Li ZG, Hall S et al (2013) Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 159(4):253–261
pubmed: 24026258 doi: 10.7326/0003-4819-159-4-201308200-00006
Lee EB, Fleischmann R, Hall S et al (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370(25):2377–2386
pubmed: 24941177 doi: 10.1056/NEJMoa1310476
Leonardi CL, Kimball AB, Papp KA et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371(9625):1665–1674
pubmed: 18486739 doi: 10.1016/S0140-6736(08)60725-4
Lightner AL, McKenna NP, Tse CS et al (2018) Postoperative outcomes in ustekinumab-treated patients undergoing abdominal operations for Crohn’s disease. J Crohns Colitis 12(4):402–407
pubmed: 29220430 doi: 10.1093/ecco-jcc/jjx163
Liu CL, Fan ST, Lo CM et al (2004) Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl 10(6):728–733
pubmed: 15162466 doi: 10.1002/lt.20144
Loomba R, Liang TJ (2017) Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology 152(6):1297–1309
pubmed: 28219691 doi: 10.1053/j.gastro.2017.02.009
Loomba R, Rowley A, Wesley R et al (2008) Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148(7):519–528
pubmed: 18378948 pmcid: 2729097 doi: 10.7326/0003-4819-148-7-200804010-00008
Ma BB, Ostrow LW, Newsome SD (2016) Disseminated zoster with paresis in a multiple sclerosis patient treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm 3(2):e203
pubmed: 27027095 pmcid: 4794808 doi: 10.1212/NXI.0000000000000203
Mallat SG, Tanios BY, Itani HS et al (2017) CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor-based regimen versus a CNI-based regimen: a systematic review and meta-analysis of randomized, controlled trials. Clin J Am Soc Nephrol 12(8):1321–1336
pubmed: 28576905 pmcid: 5544521 doi: 10.2215/CJN.13221216
Mantovani A, Dinarello CA, Molgora M, Garlanda C (2019) Interleukin-1 and related cytokines in the regulation of inflammation and immunity. Immunity 50(4):778–795
pubmed: 30995499 pmcid: 7174020 doi: 10.1016/j.immuni.2019.03.012
Martin ST, Cardwell SM, Nailor MD, Gabardi S (2014) Hepatitis B reactivation and rituximab: a new boxed warning and considerations for solid organ transplantation. Am J Transplant 14(4):788–796
pubmed: 24592928 doi: 10.1111/ajt.12649
Massenkeil G, Rackwitz S, Genvresse I, Rosen O, Dorken B, Arnold R (2002) Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 30(12):899–903
pubmed: 12476283 doi: 10.1038/sj.bmt.1703737
Masson P, Henderson L, Chapman JR, Craig JC, Webster AC (2014) Belatacept for kidney transplant recipients. Cochrane Database Syst Rev (11):CD010699
McGuigan C, Craner M, Guadagno J et al (2016) Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry 87(2):117–125
pubmed: 26492930
Mengel M, Marwedel M, Radermacher J et al (2003) Incidence of polyomavirus-nephropathy in renal allografts: influence of modern immunosuppressive drugs. Nephrol Dial Transplant 18(6):1190–1196
pubmed: 12748354 doi: 10.1093/ndt/gfg072
Merrill JT, Ginzler EM, Wallace DJ et al (2012) Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum 64(10):3364–3373
pubmed: 22674457 doi: 10.1002/art.34564
Meyer DM, Jesson MI, Li X et al (2010) Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 7:41
doi: 10.1186/1476-9255-7-41
Mikulska M, Lanini S, Gudiol C et al (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect 24(Suppl 2):S71–S82
pubmed: 29447988 doi: 10.1016/j.cmi.2018.02.003
Miller DH, Khan OA, Sheremata WA et al (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348(1):15–23
pubmed: 12510038 doi: 10.1056/NEJMoa020696
Molloy ES, Calabrese LH (2012) Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum 64(9):3043–3051
pubmed: 22422012 doi: 10.1002/art.34468
Montalban X, Hauser SL, Kappos L et al (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376(3):209–220
pubmed: 28002688 doi: 10.1056/NEJMoa1606468
Moreso F, Seron D, Morales JM et al (1998) Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses. Clin Transpl 12(3):198–205
Morgan RD, O'Callaghan JM, Knight SR, Morris PJ (2012) Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis. Transplantation 93(12):1179–1188
pubmed: 22660659 doi: 10.1097/TP.0b013e318257ad41
Morris JA, Hanson JE, Steffen BJ et al (2005) Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients. Clin Transpl 19(3):340–345
doi: 10.1111/j.1399-0012.2005.00344.x
Moskowitz CH, Nademanee A, Masszi T et al (2015) Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 385(9980):1853–1862
pubmed: 25796459 doi: 10.1016/S0140-6736(15)60165-9
Mulero P, Caminero AB, Neri Crespo MJ, Fernandez-Herranz R, Tellez LN (2012) Latent tuberculosis seems not to reactivate in multiple sclerosis patients on natalizumab. J Neuroimmunol 243(1–2):103–105
pubmed: 22226471 doi: 10.1016/j.jneuroim.2011.12.009
O'Connor P, Wolinsky JS, Confavreux C et al (2011) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365(14):1293–1303
pubmed: 21991951 doi: 10.1056/NEJMoa1014656
Palmer SM, Baz MA, Sanders L et al (2001) Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection. Transplantation 71(12):1772–1776
pubmed: 11455257 doi: 10.1097/00007890-200106270-00012
Papp KA, Langley RG, Lebwohl M et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371(9625):1675–1684
pubmed: 18486740 doi: 10.1016/S0140-6736(08)60726-6
Parikh A, Leach T, Wyant T et al (2012) Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 18(8):1470–1479
pubmed: 22147460 doi: 10.1002/ibd.21896
Peleg AY, Husain S, Kwak EJ et al (2007) Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 44(2):204–212
pubmed: 17173218 doi: 10.1086/510388
Perez CP, Patel N, Mardis CR, Meadows HB, Taber DJ, Pilch NA (2018) Belatacept in solid organ transplant: review of current literature across transplant types. Transplantation 102(9):1440–1452
pubmed: 29787522 doi: 10.1097/TP.0000000000002291
Pettit NN, Nguyen CT, Mutlu GM et al (2021) Late onset infectious complications and safety of tocilizumab in the management of COVID-19. J Med Virol 93(3):1459–1464
pubmed: 32790075 doi: 10.1002/jmv.26429
Pham C, Kuten SA, Knight RJ, Nguyen DT, Graviss EA, Gaber AO (2020) Assessment of infectious complications in elderly kidney transplant recipients receiving induction with anti-thymocyte globulin vs basiliximab. Transpl Infect Dis 22(3):e13257
pubmed: 32031729 doi: 10.1111/tid.13257
Polman CH, O'Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899–910
pubmed: 16510744 doi: 10.1056/NEJMoa044397
Pourfarziani V, Panahi Y, Assari S, Moghani-Lankarani M, Saadat SH (2007) Changing treatment protocol from azathioprine to mycophenolate mofetil: decrease in renal dysfunction, increase in infections. Transplant Proc 39(4):1237–1240
pubmed: 17524943 doi: 10.1016/j.transproceed.2007.03.006
Prajapati DN, Knox JF, Emmons J, Saeian K, Csuka ME, Binion DG (2003) Leflunomide treatment of Crohn’s disease patients intolerant to standard immunomodulator therapy. J Clin Gastroenterol 37(2):125–128
pubmed: 12869881 doi: 10.1097/00004836-200308000-00006
Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI (1989) 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 111(8):641–649
pubmed: 2802419 doi: 10.7326/0003-4819-111-8-641
Qi WX, Huang YJ, Yao Y, Shen Z, Min DL (2013) Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis. PLoS One 8(6):e65166
pubmed: 23785409 pmcid: 3681778 doi: 10.1371/journal.pone.0065166
Raisch DW, Rafi JA, Chen C, Bennett CL (2016) Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA’s adverse event reporting system. Expert Opin Drug Saf 15(8):1003–1011
pubmed: 27268272 pmcid: 5020696 doi: 10.1080/14740338.2016.1198775
Ratchford JN, Costello K, Reich DS, Calabresi PA (2012) Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod. Neurology 79(19):2002–2004
pubmed: 23035072 pmcid: 3484989 doi: 10.1212/WNL.0b013e3182735d00
Ridker PM, Everett BM, Thuren T et al (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377(12):1119–1131
pubmed: 28845751 doi: 10.1056/NEJMoa1707914
Ritter ML, Pirofski L (2009) Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transpl Infect Dis 11(4):290–297
pubmed: 19497072 pmcid: 2852585 doi: 10.1111/j.1399-3062.2009.00407.x
Roberts MB, Fishman JA (2020) Immunosuppressive agents and infectious risk in transplantation: managing the “net state of immunosuppression”. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa1189
Rousseaux C, Lefebvre B, Dubuquoy L et al (2005) Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 201(8):1205–1215
pubmed: 15824083 pmcid: 2213148 doi: 10.1084/jem.20041948
Rudick RA, Stuart WH, Calabresi PA et al (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354(9):911–923
pubmed: 16510745 doi: 10.1056/NEJMoa044396
Rutherford AI, Patarata E, Subesinghe S, Hyrich KL, Galloway JB (2018) Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford) 57(6):997–1001
doi: 10.1093/rheumatology/key023
Sadovici V, Mazur-Nicorici L, Salaru V et al (2013) Do we need to screen for latent TB when initiating a methotrexate treatment? Eur Respir J 42:P2839
Sakai R, Cho SK, Nanki T et al (2015) Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. Arthritis Res Ther 17:74
pubmed: 25880658 pmcid: 4384380 doi: 10.1186/s13075-015-0583-8
Salliot C, Dougados M, Gossec L (2009) Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 68(1):25–32
pubmed: 18203761 doi: 10.1136/ard.2007.083188
Salvana EM, Salata RA (2009) Infectious complications associated with monoclonal antibodies and related small molecules. Clin Microbiol Rev 22(2):274–290
pubmed: 19366915 pmcid: 2668229 doi: 10.1128/CMR.00040-08
Sandborn WJ, Gasink C, Gao LL et al (2012) Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med 367(16):1519–1528
pubmed: 23075178 doi: 10.1056/NEJMoa1203572
Sandborn WJ, Feagan BG, Rutgeerts P et al (2013) Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 369(8):711–721
pubmed: 23964933 doi: 10.1056/NEJMoa1215739
Sandborn WJ, Su C, Sands BE et al (2017) Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 376(18):1723–1736
pubmed: 28467869 doi: 10.1056/NEJMoa1606910
Sands BE, Sandborn WJ, Creed TJ et al (2012) Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis. Gastroenterology 143(2):356–364.e351
pubmed: 22549092 doi: 10.1053/j.gastro.2012.04.043
Sands BE, Sandborn WJ, Panaccione R et al (2019) Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 381(13):1201–1214
pubmed: 31553833 doi: 10.1056/NEJMoa1900750
Schena FP, Pascoe MD, Alberu J et al (2009) Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 87(2):233–242
pubmed: 19155978 doi: 10.1097/TP.0b013e3181927a41
Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF (2011) Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 13(5):R141
pubmed: 21884601 pmcid: 3308069 doi: 10.1186/ar3455
Schwab N, Schneider-Hohendorf T, Melzer N, Cutter G, Wiendl H (2017) Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification. Neurology 88(12):1197–1205
pubmed: 28228564 doi: 10.1212/WNL.0000000000003739
Sethi S, Peng A, Najjar R, Vo A, Jordan SC, Huang E (2021) Infectious complications in tocilizumab-treated kidney transplant recipients. Transplantation 105(8):1818–1824
pubmed: 33534530 doi: 10.1097/TP.0000000000003512
Shi Y, Moriyama T, Namba Y et al (2007) Association of treatment with 15-deoxyspergualin and BK virus nephropathy in kidney allograft recipients. Clin Transpl 21(4):502–509
doi: 10.1111/j.1399-0012.2007.00677.x
Shi Y, Wu Y, Ren Y, Jiang Y, Chen Y (2019) Infection risks of rituximab versus non-rituximab treatment for rheumatoid arthritis: a systematic review and meta-analysis. Int J Rheum Dis 22(8):1361–1370
pubmed: 31099191
Singh N (2005) Infectious complications in organ transplant recipients with the use of calcineurin-inhibitor agent-based immunosuppressive regimens. Curr Opin Infect Dis 18(4):342–345
pubmed: 15985832 doi: 10.1097/01.qco.0000172698.52408.be
Singh JA, Cameron C, Noorbaloochi S et al (2015) Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 386(9990):258–265
pubmed: 25975452 pmcid: 4580232 doi: 10.1016/S0140-6736(14)61704-9
Singh JA, Saag KG, Bridges SL Jr et al (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 68(1):1–25
doi: 10.1002/acr.22783
Skoetz N, Bauer K, Elter T et al (2012) Alemtuzumab for patients with chronic lymphocytic leukaemia. Cochrane Database Syst Rev (2):CD008078
Smolen J, Landewe RB, Mease P et al (2009) Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 68(6):797–804
pubmed: 19015207 doi: 10.1136/ard.2008.101659
Smolen JS, Pangan AL, Emery P et al (2019) Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet 393(10188):2303–2311
pubmed: 31130260 doi: 10.1016/S0140-6736(19)30419-2
Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER (2009) The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 330(3):864–875
pubmed: 19509315 doi: 10.1124/jpet.109.153973
Strangfeld A, Listing J, Herzer P et al (2009) Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301(7):737–744
pubmed: 19224750 doi: 10.1001/jama.2009.146
Sweetser MT, Dawson KT, Bozic C (2013) Manufacturer’s response to case reports of PML. N Engl J Med 368(17):1659–1661
pubmed: 23614605 doi: 10.1056/NEJMc1300283
Tanaka Y, Emoto K, Cai Z et al (2016) Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study. J Rheumatol 43(3):504–511
pubmed: 26834213 doi: 10.3899/jrheum.150613
Tang FF, Cheng YF, Xu LP et al (2020) Basiliximab as treatment for steroid-refractory acute graft-versus-host disease in pediatric patients after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 26(2):351–357
pubmed: 31704470 doi: 10.1016/j.bbmt.2019.10.031
Tedesco-Silva H, Felipe C, Ferreira A et al (2015) Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses. Am J Transplant 15(10):2655–2664
pubmed: 25988935 doi: 10.1111/ajt.13327
Thiel J, Rizzi M, Engesser M et al (2017) B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients. Arthritis Res Ther 19(1):101
pubmed: 28521808 pmcid: 5437549 doi: 10.1186/s13075-017-1306-0
Tohyama M, Yahata Y, Yasukawa M et al (1998) Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpesvirus 6. Arch Dermatol 134(9):1113–1117
pubmed: 9762024 doi: 10.1001/archderm.134.9.1113
Tse E, Leung RY, Kwong YL (2015) Invasive fungal infections after obinutuzumab monotherapy for refractory chronic lymphocytic leukemia. Ann Hematol 94(1):165–167
pubmed: 24879095 doi: 10.1007/s00277-014-2120-2
Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP (2008) Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 83(2):181–194
pubmed: 18241628 doi: 10.1016/S0025-6196(11)60839-2
van der Heijde D, Tanaka Y, Fleischmann R et al (2013) Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65(3):559–570
pubmed: 23348607 doi: 10.1002/art.37816
van Rhee F, Casper C, Voorhees PM et al (2015) A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. Oncotarget 6(30):30408–30419
pubmed: 26327301 pmcid: 4745809 doi: 10.18632/oncotarget.4655
van Vollenhoven RF, Fleischmann R, Cohen S et al (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367(6):508–519
pubmed: 22873531 doi: 10.1056/NEJMoa1112072
Vennegoor A, van Rossum JA, Polman CH, Wattjes MP, Killestein J (2015) Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler 21(12):1600–1603
pubmed: 25662344 doi: 10.1177/1352458514567728
Verstovsek S, Mesa RA, Gotlib J et al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799–807
pubmed: 22375971 pmcid: 4822164 doi: 10.1056/NEJMoa1110557
Vogelsang GB, Arai S (2001) Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings. Bone Marrow Transplant 27(12):1255–1262
pubmed: 11548843 doi: 10.1038/sj.bmt.1703076
von Hofsten J, Johnsson Forsberg M, Zetterberg M (2016) Cytomegalovirus retinitis in a patient who received ruxolitinib. N Engl J Med 374(3):296–297
doi: 10.1056/NEJMc1413918
von Muller L, Schliep C, Storck M et al (2006) Severe graft rejection, increased immunosuppression, and active CMV infection in renal transplantation. J Med Virol 78(3):394–399
doi: 10.1002/jmv.20552
Walling J (2006) From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Investig New Drugs 24(1):37–77
doi: 10.1007/s10637-005-4541-1
Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38(9):1261–1265
pubmed: 15127338 doi: 10.1086/383317
Wang K, Xu X, Fan M (2018) Induction therapy of basiliximab versus antithymocyte globulin in renal allograft: a systematic review and meta-analysis. Clin Exp Nephrol 22(3):684–693
pubmed: 28986715 doi: 10.1007/s10157-017-1480-z
Wathes R, Moule S, Milojkovic D (2013) Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med 369(2):197–198
pubmed: 23841743 doi: 10.1056/NEJMc1302135
Watson CJ, Bradley JA, Friend PJ et al (2005) Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years. Am J Transplant 5(6):1347–1353
pubmed: 15888040 doi: 10.1111/j.1600-6143.2005.00822.x
Webster AC, Ruster LP, McGee R et al (2010) Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev (1):CD003897
Winthrop KL, Baxter R, Liu L et al (2013) Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 72(1):37–42
pubmed: 22523429 doi: 10.1136/annrheumdis-2011-200690
Winthrop KL, Yamanaka H, Valdez H et al (2014) Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 66(10):2675–2684
pubmed: 24943354 pmcid: 4285807 doi: 10.1002/art.38745
Winthrop KL, Mariette X, Silva JT et al (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 24(Suppl 2):S21–S40
pubmed: 29447987 doi: 10.1016/j.cmi.2018.02.002
Wysham NG, Sullivan DR, Allada G (2013) An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest 143(5):1478–1479
pubmed: 23648912 pmcid: 5991580 doi: 10.1378/chest.12-1604
Yun H, Xie F, Delzell E et al (2016) Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in medicare. Arthritis Rheumatol 68(1):56–66
pubmed: 26315675 doi: 10.1002/art.39399
Zeyda M, Poglitsch M, Geyeregger R et al (2005) Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum 52(9):2730–2739
pubmed: 16142756 doi: 10.1002/art.21255
Zingarelli S, Frassi M, Bazzani C, Scarsi M, Puoti M, Airo P (2009) Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol 36(6):1188–1194
pubmed: 19447932 doi: 10.3899/jrheum.081246

Auteurs

Guy Handley (G)

Division of Infectious Disease and International Medicine, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.

Jonathan Hand (J)

Department of Infectious Diseases, Ochsner Health, The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA, USA. Jonathan.Hand@ochsner.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies du système immunitaire › Maladie du greffon contre l'hôte › Adverse Effects of Immunosuppression: Infections.
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation cellulaire › Transplantation de cellules souches › Transplantation de cellules souches hématopoïétiques › Adverse Effects of Immunosuppression: Infections.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Adverse Effects of Immunosuppression: Infections.
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunosuppression thérapeutique › Adverse Effects of Immunosuppression: Infections.